Compass Therapeutics, Inc. SEC filings CMPX

Compass Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to May 30, 2018. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Jun 10, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 11, 2025
DEFA14A Additional proxy material May 29, 2024 —
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 13, 2024
DEFA14A Additional proxy material Apr 27, 2023 —
DEF 14A Proxy statement Apr 27, 2023 Jun 15, 2023
DEFA14A Additional proxy material May 18, 2022 —
DEF 14A Proxy statement Apr 28, 2022 May 24, 2022
DEF 14A Proxy statement Apr 29, 2021 Jun 3, 2021

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CMPX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1738021
Former names
Olivia Ventures, Inc. (until Jun 8, 2020)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.